CD274 and non-small cell lung carcinoma: Currently, therapeutic decisions for ICI—regimens in stage IV NSCLC are based on immunohistochemistry (IHC) analyses of PD‐L1 expression in surgical specimens or on core needle biopsies (CNB) and in certain cases, with immunocytochemistry (ICC) of FNAs [7, 8, 9, 10, 11, 12].